CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: November 30, 2007
Result type: Reports
Project Number: S0118
Product Line: Common Drug Review

Generic Name: Aliskiren

Brand Name: Rasilez

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Hypertension

Submission Type: New

Project Status: Complete

Date Recommendation Issued: June 25, 2008

Recommendation Type: Do not list